CHRS News and Press, Coherus BioSciences Inc. From 01/23/24

2024-01-23 11:37:14 ET Shares of Coherus BioSciences (NASDAQ: CHRS) were sinking 8.6% lower as of 11:14 a.m. ET on Tuesday. The decline followed a nice pop for the stock on Monday after Coherus announced it was selling its Cimerli ophthalmology franchise to Sandoz Group . Th...

2024-01-22 15:41:00 ET Shares of Coherus (NASDAQ: CHRS) rallied as much as 21.7% early Monday, then gave up its gains to trade up around 2.4% as of 2:40 p.m. ET. This occurred after the company announced an agreement to divest its ophthalmology franchise. In a press release this...

2024-01-22 07:47:40 ET DENVER, Colo., Jan. 22, 2023 (www.247marketnews.com)- Coherus BioSciences, Inc. (NASDAQ: CHRS) stated, this morning, that... For further details see: Coherus (NASDAQ: CHRS) Reports $170M Cash Deal

2024-01-22 05:29:21 ET Related stories: Archer-Daniels-Midland: Great Company But Greater Short-Term Headwinds Coherus BioSciences: FDA Approvals Spice Up The Pipeline Asia-Pacific stocks mixed as traders assess economic and monetary policy outlook globally E...

2024-01-22 02:48:40 ET More on Coherus BioSciences, Sandoz Group: Coherus BioSciences: FDA Approvals Spice Up The Pipeline Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval Sandoz Group: Novartis Spinoff With A Double-Digit EBITDA CAGR Through 2028 ...

– Transaction aligns to Coherus’ strategic focus on oncology – – Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: ...

2024-01-19 07:29:39 ET More on Coherus BioSciences Coherus BioSciences: FDA Approvals Spice Up The Pipeline Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval Coherus: The Surface Acquisition Is A Distraction Coherus ends Junshi-partnered TIGI...

– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses – – Data support casdozo as a promising novel immuno-oncology agent with clinical activity in liver cancer that may be associat...

2024-01-17 17:51:36 ET Summary CHRS has a pipeline of biosimilars including Yusimry, Cimerli, and Udenyca. A new form of Udenyca, Udenyca Onbody, was approved in December 2023. CHRS also has a new drug Loqtorzi (toripalimab) which was approved in the US for the treatment of nasoph...

2024-01-10 07:24:49 ET More on Coherus BioSciences Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval Coherus: The Surface Acquisition Is A Distraction Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript Coherus gets FDA approval...